Quest Partners LLC Makes New $669,000 Investment in DaVita Inc. (NYSE:DVA)

Quest Partners LLC purchased a new position in DaVita Inc. (NYSE:DVA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,081 shares of the company's stock, valued at approximately $669,000.

Other hedge funds have also recently modified their holdings of the company. Bessemer Group Inc. lifted its position in DaVita by 2,335.6% during the 1st quarter. Bessemer Group Inc. now owns 10,741 shares of the company's stock worth $1,483,000 after acquiring an additional 10,300 shares during the period. BOKF NA boosted its position in DaVita by 286,550.0% in the first quarter. BOKF NA now owns 5,733 shares of the company's stock valued at $790,000 after buying an additional 5,731 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in DaVita by 29.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company's stock worth $6,942,000 after buying an additional 11,454 shares during the period. Comerica Bank lifted its stake in DaVita by 41.4% during the 1st quarter. Comerica Bank now owns 34,431 shares of the company's stock valued at $4,753,000 after acquiring an additional 10,074 shares during the period. Finally, MBB Public Markets I LLC purchased a new stake in shares of DaVita in the 2nd quarter valued at $582,000. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Price Performance

DaVita stock traded up $1.37 during midday trading on Friday, reaching $165.51. The company had a trading volume of 612,123 shares, compared to its average volume of 1,021,709. DaVita Inc. has a 12-month low of $98.26 and a 12-month high of $168.50. The firm's fifty day simple moving average is $158.31 and its 200-day simple moving average is $148.36. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The company has a market capitalization of $13.57 billion, a P/E ratio of 17.85, a P/E/G ratio of 0.93 and a beta of 0.89.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same period in the prior year, the firm earned $2.85 earnings per share. The business's revenue was up 4.6% on a year-over-year basis. As a group, equities analysts anticipate that DaVita Inc. will post 9.71 EPS for the current year.

Insider Transactions at DaVita

In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Joel Ackerman sold 64,029 shares of the company's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares of the company's stock, valued at approximately $17,286,243.86. The trade was a 36.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 156,086 shares of company stock valued at $24,807,161 over the last 90 days. 2.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Barclays boosted their target price on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research report on Thursday, October 31st. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 8th. Truist Financial upped their price objective on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. Finally, Bank of America lifted their target price on shares of DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.